Cite
HARVARD Citation
Zelniker, T. et al. (2019). SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 393 (10166), pp. 31-39. [Online].